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AZATHIOPRINE-RELATED BONE MARROW TOXICITY AND 
LOW ACTIVITIES OF PURINE ENZYMES IN PATIENTS 
WITH RHEUMATOID ARTHRITIS
PIT J. S. M. KERSTENS, JAN N. STOLK, RONNEY A. De ABREU, LAMBERT H. J. LAMBOOY,
LEO B. A. van de PUTTE, and AGNES A. M. T. BOERBOOMS
Objective. Azathioprine (AZA) metabolism 
largely parallels the endogenous purine pathways. To 
date, thiopurine methyltransferase (TPMT) deficiency 
has been reported as a cause of AZA-related bone 
marrow toxicity in 1 patient with rheumatoid arthritis 
(RA). We therefore studied purine enzyme activities in 3 
patients with RA who experienced AZA-related bone 
marrow toxicity.
Methods. Lymphocyte activity of purine nucleo­
side phosphorylase and 5'-nucleotidase (5NT) and eryth­
rocyte activity of TPMT, key enzymes in thiopurine 
catabolism, were measured in 3 RA patients who had 
experienced AZA-related bone marrow toxicity and in 
16 RA patients without signs of toxicity despite at least 6 
months of treatment with AZA.
Results. Two patients with AZA-related bone 
marrow toxicity were found to have a TPMT deficiency, 
1 partial and 1 total. In the third patient, 5NT activity 
was found to be well below the lowest level observed in 
the control subjects.
Conclusion. All 3 patients with severe AZA- 
related bone marrow toxicity had abnormal purine 
enzyme activities. Deficiency of purine enzymes, includ­
ing TPMT and 5NT, may be a cause of AZA-related 
bone marrow toxicity in patients with RA.
Acute, severe bone marrow toxicity is a rela­
tively rare but potentially life-threatening side effect of
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azathioprine (AZA) when it is taken in dosages com­
monly prescribed for the treatment of rheumatoid 
arthritis (RA) (<3 mg/kg/day). After conversion to 
6-mercaptopurine, the metabolism of AZA parallels 
the endogenous purine pathways (Figure 1). Low 
activity of thiopurine methyltransferase (TPMT) has 
occasionally been reported as a cause of AZA-related 
bone marrow toxicity in patients with a variety of 
conditions, including 1 with RA (1-3). However, other 
mechanisms must be present as well, since normal 
TPMT activity was found in 9 renal transplant patients 
with leukopenia attributed to AZA (4). To date, no 
cases of AZA-related bone marrow toxicity associated 
with abnormalities in purine enzymes have been re­
ported in the rheumatology literature. We studied the 
activities of 3 key enzymes of purine catabolism in 3 
patients with RA who experienced AZA-related bone 
marrow toxicity and in 16 control patients with RA.
PATIENTS AND METHODS
Control RA patients. Sixteen patients (9 male, 7 
female) with RA (15 rheumatoid factor [RF] positive) with 
normal liver and kidney function, who had shown no bone 
marrow toxicity after at least 6 months of treatment with 
AZA (1-3 mg/kg day) served as the control group.
Patients. Three patients who experienced acute 
AZA-related bone marrow toxicity were studied. Patient 1, a 
63-year-old man with RF-positive RA since 1973, had been 
treated with aurothioglucose 40 mg monthly for >10 years 
when AZA 2.0 mg/kg daily was added to his treatment 
regimen because of active polyarthritis with nodules and 
vasculitic cutaneous ulcers. Except for slight anemia, hema­
tologic parameters and kidney function were normal at that 
time. After 4 weeks, pancytopenia developed, and both AZA 
and aurothioglucose had to be discontinued (Table 1). Pred­
nisone (40 mg/day) was started, and within 2 weeks, the 
hematologic parameters improved (hemoglobin 6.1 mmoles/ 
liter, white blood cell [WBC] count 5.8 x 109/liter, platelet 
count 402 x 109/liter). At that time aurothioglucose, 50 mg
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Figure 1. Pathways in thiopurine metabolism. TPMT = thiopurine 
methyltransferase; Me-t = methyl-thiopurine (t = thio); 5NT = 
5'-nucleotidase; HGPRT = hypoxanthine-guanine-phosphoribosyl- 
transferase; PNP = purine nucleoside phosphorylase; XO =  xan- 
thineoxidase.
biweekly, was recommenced. Over a followup period of Wi 
years, no hematologic problems have reoccurred.
Patient 2, a 49-year-old woman who had RF-positive 
RA since 1974, has been described in more detail elsewhere 
(5). Previous treatment consisted of hydroxychloroquine, 
aurothioglucose, and D-penicillamine. The latter had to be 
discontinued because of mild leukopenia (2.4 x 109/liter) and 
thrombocytopenia (60 x 109/liter). Hematologic parameters 
returned to normal after discontinuation of the D-penicilla­
mine. Approximately 2 years later, AZA (1.5 mg/kg/day) was 
started because of active disease. Four weeks later, pancy­
topenia necessitated the withdrawal of AZA (Table 1). 
Platelet transfusions had to be given and prednisone (60 
mg/day) was started, but the prednisone dosage could be 
tapered rapidly. After 3 weeks, only slight anemia remained 
(hemoglobin 6.1 mmoles/liter), and the WBC and platelet 
counts had returned to normal.
Patient 3, a 57-year-old man with RF-positive RA 
since 1972, has recently been described elsewhere (6). Clin­
ical data are summarized in Table I.
Laboratory assessments. Lymphocyte activities of 
5'-nucleotidase (5NT) and purine nucleoside phosphorylase 
(PNP) and erythrocyte activities of TPMT were measured
Table 2 . TPMT and 5NT activities in 3 rheumatoid arthritis pa­
tients with azathioprine-related bone marrow toxicity and 16 control 
rheumatoid arthritis patients (controls)*
Controls,
median
(range)
Patient
1
Patient
2
Patient
3
TPMT 22.75
(12.24-41.11)
7.43 0 28.15
5 NT 7.42
(3.72-19.18)
9.55 5.52 2.49+
* TPMT = thiopurine methyltransferase (pmoles/10" 6 erythrocytes/ 
hour“ 1); 5NT = 5'-nucleotidase (nmoles/10 ”6 íymphocytes/hour'"1). 
t  See also ref. 6 .
according to methods described previously (7,8). Briefly, for 
PNP and 5NT activities, after cell separation by a Percoll 
gradient, lymphocyte numbers were determined in a Coulter 
counter (Coulter Electronics, Luton, England), and exact 
numbers of cells were collected in Eppendorf tubes for each 
assay. The cell suspension was freeze-dried and enzyme 
assays were carried out by a previously described radio­
chemical micromethod (7). PNP was assayed in the anabolic 
direction, by which 14C-labeied hypoxanthine is converted 
into l4C-labeled inosine. Total 5NT was measured by the 
degradation of 14C-labeled AMP to 14C-labeled adenosine. 
For the TPMT assay an erythrocyte lysate was transferred 
(without the “ghost cells”) to 1-ml Eppendorf tubes and 
frozen at -70°C until further use. TPMT activity was deter­
mined by measuring the methyl-transfer of S-adenosyl-L- 
[methyl-I4C]-methionine to 6-[methyl-14C]-mercaptopurine 
(8,9). Activities of 5NT and PNP were expressed in nmoles/ 
10-6 lymphocytes/hour"1, and TPMT in pmoles/10~6 eryth­
rocytes/hour-1 . All assays were performed in quadruplicate.
RESULTS
Blood samples for measurement of purine en­
zyme activities in the patients were obtained at least 3 
months after hematologic abnormalities had resolved. 
None of the subjects studied had received blood 
transfusions within the 4 months prior to blood draw­
ing for purine enzyme measurement. All subjects had 
normal kidney and liver function test results and
Table 1 . Three rheumatoid arthritis patients with azathioprine (AZA)-related bone marrow toxicity
Patient
AZA
dosage
(mg/kg/day)
Days of  
AZA
treatment*
Before AZA At nadir
Hemoglobin
(mmoles/liter)
WBCt
(x  IO9/!iter)
Platelets 
(x  109/liter)
Hemoglobin
(mmoles/liter)
WBC 
(x  109/liter)
Platelets
(X  10‘Vliter)
1 2 . 0 30 6.7 6 . 0 303 4.5 1.4 1 0 2
2 1.5 28 7.4 3.9 188 4.9 1.4 4
3$ 1 .8 56 7.5 4.1 296 7.2 0 . 8 280
* Number of treatment days before bone marrow toxicity occurred, 
t  WBC =  white blood cell count.
$ See also ref. 6 .
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normal serum urate levels. The mean coefficient of 
variation within assays was 0.10, 0.07, and 0.03 for 
5NT, PNP, and TPMT, respectively. Interassay vari­
ation (5 controls, 3 consecutive weeks) ranged be­
tween 0.10 and 0.19 for 5NT, between 0.05 and 0.23 
for PNP, and between 0.04 and 0.07 for TPMT. PNP 
activity in patients experiencing AZA-related bone 
marrow toxicity was within the range of values found 
in the control group (data not shown). Patient i was 
found to have a complete TPMT deficiency, and 
TPMT activity was diminished in patient 2. 5NT 
activity was low in patient 3 when compared with the 
control subjects (Table 2).
DISCUSSION
All 3 patients with acute azathioprine-related 
bone marrow toxicity had a deficiency of 1 of the 
purine enzymes measured. Two o f them had a TPMT 
deficiency, 1 complete and 1 partial. In the third 
patient, low  activity o f 5NT was found. The formation 
o f cytotoxic thionucleotides and their feedback inhibi­
tion on de novo purine synthesis are considered to be 
responsible for both the therapeutic and the adverse 
effects of purine analogs. Impaired catabolism of thio- 
purines will lead to the accumulation of thionucleo­
tides and enhance cytotoxicity (Figure 1); bone mar­
row depression during concurrent use of AZA and 
allopurinol, a xanthine oxidase antagonist, is an exam­
ple o f this (5,10). None of the patients described herein 
was taking allopurinol at the time bone marrow toxi­
city occurred, and the absence o f  decreased serum 
urate levels sufficiently excludes the possibility of 
xanthine oxidase deficiency as a cause of AZA toxicity.
TPMT is inherited in an autosomal codominant 
manner and shows a wide range of activity in the 
healthy population (9,11,12). Approximately 1 in 300 
individuals has a complete deficiency of TPMT, and 
11% show intermediate activity (8,9). Thus far, TPMT 
deficiency as a cause o f AZA-related bone marrow 
depression has been reported in 8 patients (1-3), 
including 1 with RA (1). It was found to be associated 
with high levels o f 6-thioguanine-nucleotide (1).
Our observations in patients 1 and 2 confirm the 
association of TPMT deficiency with AZA-related 
bone marrow toxicity. Activity o f 5NT measured in 
patient 3 was well below the low est value found in the 
RA patients who served as a control group. This 
condition may lead to increased levels o f thionucleo­
tides, causing increased susceptibility to bone marrow 
toxicity during treatment with AZA.
Two major forms of 5NT are recognized: ecto- 
5NT and cytosolic 5NT (13). Ecto-5NT is located on 
outer membranes, which are not permeable for thio­
nucleotides, and most likely plays no role in the 
intracellular thiopurine metabolism and its subsequent 
cytotoxicity (14,15). This is supported by the observa­
tion that in vitro drug resistance to 6-thioguanine in 
childhood lymphoblastic leukemia is not related to 
ecto-5NT activity and is associated with high cytosolic 
5NT activity (16). Our assay measured total 5NT  
activity. It seem s reasonable that low cytosolic 5NT 
would account for the low total 5NT activity levels we 
recently found to be associated with AZA-related bone 
marrow toxicity in 3 patients, including the 1 reported 
here and 2 renal transplant recipients (6). 5NT activity 
varies between lymphocyte subsets and with matura­
tion state. Although the use of a control group of 
patients with RA, all o f whom had taken AZA, makes 
it less likely that such differences will have influenced 
our results, this possibility cannot be fully excluded.
In conclusion, deficiency of purine enzymes, in­
cluding TPMT and 5NT, may be a cause of azathioprine- 
related bone marrow toxicity. If low activity o f TPMT 
or 5NT is found in a patient who is believed to have 
AZA-related bone marrow toxicity, a rechallenge 
should be avoided, or, when inevitable, the drug 
should be started at a lower dosage and with close 
monitoring o f hematologic parameters. In relatives of 
a person who has experienced AZA-related bone 
marrow toxicity or one who has been shown to have a 
TPMT deficiency, determination of TPMT activity 
before the start o f AZA treatment is suggested. Al­
though at present, measurement of purine enzymes is 
laborious, it is conceivable that when methods become 
less expensive and more readily available, this poten­
tially life-threatening side effect o f AZA can be pre­
vented.
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